JPS6426517A - Remedy for dysuria - Google Patents

Remedy for dysuria

Info

Publication number
JPS6426517A
JPS6426517A JP62181579A JP18157987A JPS6426517A JP S6426517 A JPS6426517 A JP S6426517A JP 62181579 A JP62181579 A JP 62181579A JP 18157987 A JP18157987 A JP 18157987A JP S6426517 A JPS6426517 A JP S6426517A
Authority
JP
Japan
Prior art keywords
dysuria
patient
urine
remedy
action
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP62181579A
Other languages
Japanese (ja)
Inventor
Hiroyuki Koike
Takeshi Oshima
Fumitoshi Asai
Hiroshi Fukumi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sankyo Co Ltd
Original Assignee
Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co Ltd filed Critical Sankyo Co Ltd
Priority to JP62181579A priority Critical patent/JPS6426517A/en
Publication of JPS6426517A publication Critical patent/JPS6426517A/en
Pending legal-status Critical Current

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

PURPOSE:To obtain a low-toxic remedy for dysuria, exhibiting alpha1-adrenoreceptor blocking action in urinary tract and continuing the action over a long period, by using a compound known to exhibit slow hypotensive action as an active component. CONSTITUTION:The objective remedy for dysuria contains the compound of formula or its pharmacologically allowable acid addition salt (especially preferably hydrochloride) as an active component. The remedying object is a patient complaining dysuria, incontinence of urine, pollakiuria, etc., as subjective symptoms. It is effective to a patient of neurogenic vesical dysuria and a patient of prostate gland obstruction accompanying or without accompanying prostatomegaly to increase the flow rate of urine and decrease the residual urine.
JP62181579A 1987-07-21 1987-07-21 Remedy for dysuria Pending JPS6426517A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP62181579A JPS6426517A (en) 1987-07-21 1987-07-21 Remedy for dysuria

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP62181579A JPS6426517A (en) 1987-07-21 1987-07-21 Remedy for dysuria

Publications (1)

Publication Number Publication Date
JPS6426517A true JPS6426517A (en) 1989-01-27

Family

ID=16103273

Family Applications (1)

Application Number Title Priority Date Filing Date
JP62181579A Pending JPS6426517A (en) 1987-07-21 1987-07-21 Remedy for dysuria

Country Status (1)

Country Link
JP (1) JPS6426517A (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0416841A2 (en) * 1989-09-06 1991-03-13 Hitachi Chemical Co., Ltd. Novel use of 6-[[3-[4-(2- methoxyphenyl)-1-piperazinyl] propyl]amino]-1,3-dimethyluracil for preparing a pharmaceutical for treating urinary obstruction
US5075308A (en) * 1989-08-31 1991-12-24 Hitachi Chemical Co., Ltd. Method for treating urinary obstruction
WO1992018129A1 (en) * 1991-04-18 1992-10-29 Bernard Aranda Use of piribedil derivatives and analogues for the treatment of hyperactive or unstable bladders
US6602888B2 (en) 1992-11-13 2003-08-05 Synaptic Pharmaceutical Corporation Use of α1C specific compounds to treat benign prostatic hyperplasia
WO2005007155A1 (en) * 2003-07-16 2005-01-27 Kyowa Hakko Kogyo Co., Ltd. Medicinal composition
WO2005089742A1 (en) * 2004-03-24 2005-09-29 Kissei Pharmaceutical Co., Ltd. Medicine for prevention or treatment of frequent urination or urinary incontinence

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5075308A (en) * 1989-08-31 1991-12-24 Hitachi Chemical Co., Ltd. Method for treating urinary obstruction
EP0416841A2 (en) * 1989-09-06 1991-03-13 Hitachi Chemical Co., Ltd. Novel use of 6-[[3-[4-(2- methoxyphenyl)-1-piperazinyl] propyl]amino]-1,3-dimethyluracil for preparing a pharmaceutical for treating urinary obstruction
US5145851A (en) * 1989-09-06 1992-09-08 Hitachi Chemical Co., Ltd. Method for treating urinary obstruction
WO1992018129A1 (en) * 1991-04-18 1992-10-29 Bernard Aranda Use of piribedil derivatives and analogues for the treatment of hyperactive or unstable bladders
US5362731A (en) * 1991-04-18 1994-11-08 Bernard Aranda Use of piribedil derivatives and analogs for the treatment of hyperactive or unstable bladders
US6602888B2 (en) 1992-11-13 2003-08-05 Synaptic Pharmaceutical Corporation Use of α1C specific compounds to treat benign prostatic hyperplasia
WO2005007155A1 (en) * 2003-07-16 2005-01-27 Kyowa Hakko Kogyo Co., Ltd. Medicinal composition
WO2005089742A1 (en) * 2004-03-24 2005-09-29 Kissei Pharmaceutical Co., Ltd. Medicine for prevention or treatment of frequent urination or urinary incontinence

Similar Documents

Publication Publication Date Title
Harris et al. Helicobacter pylori urease is a potent stimulus of mononuclear phagocyte activation and inflammatory cytokine production
ATE395056T1 (en) USE OF R-(+)-2-(3-DIISOPROPYLAMINO-1-PHENYLPROPYL)-4-HYDROXY-METHYL-PHENYLISOBUTYRIC ACID ESTER HYDROGEN FUMARATE FOR THE TREATMENT OF URINARY INCONTINENCE AND OTHER SPASMOGENIC CONDITIONS
FI935675A0 (en) Pyrazolopyrimidiner
DE69931794D1 (en) THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF SLUDGE HYPERSECRETION
WO2001039759A3 (en) Sulfonic acid or sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds
DE69108048D1 (en) DERIVATIVES OF HYDROXAMIC ACID AND N-HYDROXY URINE, AND THEIR USE.
BR0313371A (en) Compound, use of a compound and disease treatment method
DE60021873D1 (en) PREPARATION FOR THE PROPHYLAXIS OR TREATMENT OF DEMENTIA DISEASE CONTAINS A HYDROXYZIMOTE ACID DERIVATIVE OR AN EXTRACT OF A PLANT OF THE GENUS ANGELICA CONTAINING THIS ACID.
DE69006684D1 (en) Use of a composition for the manufacture of a medicament for the treatment of the symptoms of abstinence.
DE69833059D1 (en) Use of botulinum toxin for the treatment of urinary incontinence
MA25809A1 (en) ARYLMETHYLAMINE DERIVATIVES FOR USE AS TRYPTASE INHIBITORS
BR9917038A (en) Compound, pharmaceutical composition, method of modulating chemokine receptor activity, method of treatment or prevention of inflammatory diseases, method of treatment or prevention of asthma and method of treatment or prevention of inflammatory disorders
EA199900669A1 (en) INTERMEDIATE COMPOUNDS FOR OBTAINING N-[AMINOIMINOMETHYL OR AMINOMETHYL-PHENYL] SUBSTITUTED PROPYLAMIDES
EA199900542A1 (en) COMPOUNDS OF SULPHONIC ACID OR SULPHONYLAMINO-N- (HETEROARALKYL) -ASAGHETHROCYCLOSYME
BR9910899A (en) N- (hetero-aralkyl) -azaeterocyclamide sulfonic or sulfonylamino compounds
GB2075341B (en) Pharmaceutical compositions
JPS6426517A (en) Remedy for dysuria
DE69210654D1 (en) Use of tomoxetine to treat dysfunction of the lower urinary tract
WO2002096362A3 (en) Method for treating fibrotic diseases or other indications vi
EP1284265A4 (en) Benzothiophene derivatives and medicinal use thereof
DE69727378D1 (en) USE OF 5-HTIA RECEPTOR ANTAGONISTS FOR TREATING URINE INCONTINENCE
WO2001003688A3 (en) Treatment of cyclooxygenase-2 mediated disorders using conjugated fatty acid compounds
ATE442137T1 (en) MEDICATION FOR THE PREVENTION OR TREATMENT OF FREQUENT URINATION OR URINARY INCONTINENCE
ATE277926T1 (en) TRIZYCLIC VASOPRESSIN AGONISTS
ATE192040T1 (en) ACTIVE INGREDIENTS AGAINST ARTERIOSCLEROSIS